Sean Maduck, President of Corcept Therapeutics (NASDAQ:CORT), executed stock transactions on June 1 and 2, 2026, selling 25,000 shares for approximately $1.76 million. The stock price has shown a significant increase of 109% year-to-date, currently trading at $72.68. Maduck's sales were part of a Rule 10b5-1 trading plan initiated in December 2025, and he also exercised options to acquire 25,000 shares at an exercise price of $8.27 per share. Despite a reported net loss of $31.8 million in the first quarter of 2026, Corcept raised its revenue guidance for the year, buoyed by the launch of its product Lifyorli. Notably, the company presented encouraging results at the American Society of Clinical Oncology Annual Meeting, showing that Lifyorli combined with nab-paclitaxel reduced the risk of death by 35% for patients with platinum-resistant ovarian cancer. Following these developments, H.C. Wainwright upgraded its price target for Corcept from $65 to $75.